HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients. (Q39331730)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22696054%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22696054%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

0 references

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22696054%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

David Laurin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22696054%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Laurence Chaperot

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22696054%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Julie Charles

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22696054%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

2

Marie-Therese Leccia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22696054%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

7

Joel Plumas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22696054%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Dimitri Salameire

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22696054%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

language of work or name

English

0 references

publication date

14 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22696054%20AND%20SRC:MED&resulttype=core&format=json

Journal of Investigative Dermatology

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22696054%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

132

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22696054%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22696054%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

2395-2406

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22696054%20AND%20SRC:MED&resulttype=core&format=json

describes a project that uses

5 February 2020

GEN2.2

0 references

cites work

Plasmacytoid dendritic cell precursors induce allogeneic T-cell hyporesponsiveness and prolong heart graft survival

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Plasmacytoid dendritic cells in immunity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Melanoma in 2011: a new paradigm tumor for drug development

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

The allogeneic response and tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Focus on adoptive T cell transfer trials in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Next generation of immunotherapy for melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Therapeutic cancer vaccines: are we there yet?

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Melanoma vaccines: developments over the past 10 years.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Cancer regression in patients after transfer of genetically engineered lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Preliminary evidence that the allogeneic response might trigger antitumour immunity in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Recent developments in cancer vaccines

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Building on dendritic cell subsets to improve cancer vaccines

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Plasmacytoid dendritic cells prime IFN-γ-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Targeted therapies: Improved outcomes for patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Antigen-presentation properties of plasmacytoid dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Differential MHC class II synthesis and ubiquitination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Treatment of cutaneous metastatic melanoma with imiquimod 5% cream and the pulsed-dye laser

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.152

7 January 2021

Identifiers

DOI

10.1038/JID.2012.152

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22696054%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference